Literature DB >> 8398694

Direct comparison of a radioiodinated intact chimeric anti-CEA MAb with its F(ab')2 fragment in nude mice bearing different human colon cancer xenografts.

C A Vogel1, A Bischof-Delaloye, J P Mach, A Pèlegrin, N Hardman, B Delaloye, F Buchegger.   

Abstract

Tumour localisation and tumour to normal tissue ratios of a chimeric anti-carcinoembryonic antigen (CEA) monoclonal antibody (MAb), in intact form and as an F(ab')2 fragment labelled with 125I and 131I, were compared in groups of nude mice bearing four different colon cancer xenografts, T380, Co112 or LoVo, of human origin, or a rat colon cancer transfected with human CEA cDNA, called '3G7'. For each tumour, three to four mice per time point were analysed 6, 12, 24, 48 and 96 h after MAb injection. In the different tumours, maximal localisation of intact MAb was obtained at 24 to 48 h, and of F(ab')2 fragment 12 to 24 h after injection. Among the different tumours, localisation was highest with colon cancer T380, with 64% of the injected dose per gram (% ID/g) for the intact MAb and 57% for its F(ab')2 fragment, while in the three other tumours, maximal localisation ranged from 14 to 22% ID g-1 for the intact MAb and was about 11% for the F(ab')2. Tumour to normal tissue ratios of intact MAb increased rapidly until 24 h after injection and remained stable or showed only a minor increase thereafter. In contrast, for the F(ab')2 fragment, the tumour to normal tissue ratios increased steadily up to 4 days after injection reaching markedly higher values than those obtained with intact MAb. For the four different xenografts, tumour to blood ratios of F(ab')2 were about 2, 3 and 5 to 16 times higher than those of intact antibodies at 12, 24 and 96 h after injection, respectively.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8398694      PMCID: PMC1968595          DOI: 10.1038/bjc.1993.410

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  30 in total

1.  The use of paired labeling in the determination of tumor-localizing antibodies.

Authors:  D PRESSMAN; E D DAY; M BLAU
Journal:  Cancer Res       Date:  1957-10       Impact factor: 12.701

2.  Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials.

Authors:  H B Breitz; P L Weiden; J L Vanderheyden; J W Appelbaum; M J Bjorn; M F Fer; S B Wolf; B A Ratliff; C A Seiler; D C Foisie
Journal:  J Nucl Med       Date:  1992-06       Impact factor: 10.057

3.  Establishment of a human carcinoembryonic antigen-producing colon adenocarcinoma cell line.

Authors:  B Drewinko; M M Romsdahl; L Y Yang; M J Ahearn; J M Trujillo
Journal:  Cancer Res       Date:  1976-02       Impact factor: 12.701

4.  In vivo localisation of radiolabelled antibodies to carcinoembryonic antigen in human colon carcinoma grafted into nude mice.

Authors:  J P Mach; S Carrel; C Merenda; B Sordat; J C Cerottini
Journal:  Nature       Date:  1974-04-19       Impact factor: 49.962

5.  Preparation of F(ab')2 fragments from mouse IgG of various subclasses.

Authors:  E Lamoyi; A Nisonoff
Journal:  J Immunol Methods       Date:  1983-01-28       Impact factor: 2.303

6.  Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49.

Authors:  D E Milenic; T Yokota; D R Filpula; M A Finkelman; S W Dodd; J F Wood; M Whitlow; P Snoy; J Schlom
Journal:  Cancer Res       Date:  1991-12-01       Impact factor: 12.701

7.  Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability.

Authors:  S Folli; A Pèlegrin; Y Chalandon; X Yao; F Buchegger; D Lienard; F Lejeune; J P Mach
Journal:  Int J Cancer       Date:  1993-03-12       Impact factor: 7.396

8.  Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody.

Authors:  D Colcher; M Zalutsky; W Kaplan; D Kufe; F Austin; J Schlom
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

9.  Different behaviour of mouse-human chimeric antibody F(ab')2 fragments of IgG1, IgG2 and IgG4 sub-class in vivo.

Authors:  F Buchegger; A Pèlegrin; N Hardman; C Heusser; J Lukas; W Dolci; J P Mach
Journal:  Int J Cancer       Date:  1992-02-01       Impact factor: 7.396

10.  Human carcinoembryonic antigen cDNA expressed in rat carcinoma cells can function as target antigen for tumor localization of antibodies in nude rats and as rejection antigen in syngeneic rats.

Authors:  A Pèlegrin; A Terskikh; D Hayoz; Y Chalandon; N O Olsson; S Folli; F Buchegger; B Kromer; K Schwarz; M Martin
Journal:  Int J Cancer       Date:  1992-08-19       Impact factor: 7.396

View more
  7 in total

1.  Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology.

Authors:  Scott M Knowles; Anna M Wu
Journal:  J Clin Oncol       Date:  2012-09-17       Impact factor: 44.544

2.  In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.

Authors:  Christel Larbouret; Nadège Gaborit; Thierry Chardès; Mickaël Coelho; Emmanuelle Campigna; Caroline Bascoul-Mollevi; Jean-Pierre Mach; David Azria; Bruno Robert; André Pèlegrin
Journal:  Neoplasia       Date:  2012-02       Impact factor: 5.715

3.  Preclinical evaluation of a novel CEA-targeting near-infrared fluorescent tracer delineating colorectal and pancreatic tumors.

Authors:  Martin C Boonstra; Berend Tolner; Boudewijn E Schaafsma; Leonora S F Boogerd; Hendrica A J M Prevoo; Guarav Bhavsar; Peter J K Kuppen; Cornelis F M Sier; Bert A Bonsing; John V Frangioni; Cornelis J H van de Velde; Kerry A Chester; Alexander L Vahrmeijer
Journal:  Int J Cancer       Date:  2015-06-22       Impact factor: 7.396

4.  The multicompartmental p32/gClqR as a new target for antibody-based tumor targeting strategies.

Authors:  David Sánchez-Martín; Angel M Cuesta; Valentina Fogal; Erkki Ruoslahti; Luis Alvarez-Vallina
Journal:  J Biol Chem       Date:  2010-12-14       Impact factor: 5.157

Review 5.  Radiolabelled monoclonal antibodies in tumour imaging and therapy: out of fashion?

Authors:  A B Delaloye; B Delaloye
Journal:  Eur J Nucl Med       Date:  1995-06

Review 6.  Review: update on selection of optimal radiopharmaceuticals for clinical trials.

Authors:  Lawrence E Williams; George Lopatin; Daniel D Kaplan; An Liu; Jeffrey Y C Wong
Journal:  Cancer Biother Radiopharm       Date:  2008-12       Impact factor: 3.099

7.  Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab')2 fragments of an anti-tumour antibody.

Authors:  D Marshall; R B Pedley; R G Melton; J A Boden; R Boden; R H Begent
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.